Resource library - Median Technologies

Immunotherapies display novel response patterns that affect the design of imaging based studies and the subsequent evaluation of imaging data. Applying traditional chemotherapy-based response assumptions to immunotherapy trials can result in inaccurate interpretation of response, premature therapy termination, and unnecessary removal of subjects from a trial. Our unique solutions for medical image analysis and management and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy.

Elton Rexhepaj [1], Corinne Ramos [1], Nozha Boujemaa [1], Benoit Huet [1] -Affiliations: [1] Median Technologies, Valbonne, France, in col. with: Olivier Lucidarme. Corresponding author e-mail: elton.rexhepaj@mediantechnologies.com

Poster presented at AASLD: The liver meeting 2019 conference | Nov 8-12, 2019 |Boston (USA).

The diagnosis of hepatic fibrosis within liver disease is important for prognosis, stratification for treatment and monitoring of treatment. Although liver biopsy is considered the gold standard for staging fibrosis, it has its limitations due to its invasive nature, sampling error and inter-observer variability. Previous studies have shown that computer tomography (CT) perfusion imaging and splenic radiomics can accurately assess and grade liver fibrosis.